Clinical trials: sponsored by British Columbia Cancer Agency
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA
The purpose of this study is to assess the strategy in treatment selection using ctDNA fraction as a predictive biomarker to direct treatment decision (ctDNA fraction <2% receives enzalutamide, and ctDNA fraction ≥2% receives…
- Trial name
- PROTRACT (NCT04015622)
- Testing
- Enzalutamide, Docetaxel
- Where
- 7 sites in Canada
- Volunteers
- 100 people
- Sponsor
- British Columbia Cancer Agency
Cancer
PRecision Oncology Evidence Development in Cancer Treatment - Clinical: PREDiCTc
This pilot clinical trial aims to assess the real world quality of life and survival of patients treated with targeted therapy that has preliminary evidence of efficacy in subjects with advanced rare cancers or cancer harbouring…
- Trial name
- PREDiCTc (NCT04814095)
- Testing
- QOL, CT imaging
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- British Columbia Cancer Agency
Cancer
PRecision Oncology Evidence Development in Cancer Treatment - Liquid
The current standard of care for molecular characterization of tumors is tissue based next generation sequencing (NGS) panel. Liquid biopsies (ie blood) are of increasing interest and have been implemented as a diagnostic tool in…
- Trial name
- PREDiCTl (NCT05057234)
- Testing
- FoundationOne liquid CDx, Quality of life questionnaires
- Where
- Canada
- Volunteers
- 1,500 people
- Sponsor
- British Columbia Cancer Agency
EGFR Activating Mutation, Leptomeningeal Metastasis
CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease
Leptomeningeal disease is malignant seeding of the leptomeninges and presents with a variety of symptoms frequently impacting quality of life.
- Conditions
- EGFR Activating Mutation, Leptomeningeal Metastasis, Non Small Cell Lung Cancer
- Trial name
- NCT05257967
- Testing
- Lumbar puncture and Phlebotomy
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- British Columbia Cancer Agency
Cancer
Evidence Development in Cancer Treatment - Real World: PREDiCTrw
This pilot clinical trial aims to assess the real world quality of life and survival of patients treated with therapy that has preliminary evidence of efficacy but uncertainty of the magnitude of clinical benefit or cost…
- Trial name
- NCT06242912
- Testing
- QOL - quality of life, Radiographic or laboratory evaluation
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- British Columbia Cancer Agency
B-Cell Leukemia, Non-Hodgkin's Lymphoma
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
This is a phase I dose-finding trial of an autologous CD22 targeting chimeric antigen receptor (CAR)-T cell product, called CLIC-2201, for participants with relapsed/refractory B cell malignancies.
- Conditions
- B-Cell Leukemia, Non-Hodgkin's Lymphoma, B-cell Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma
- Trial name
- NCT06208735
- Testing
- CLIC-2201
- Where
- 7 sites in Canada
- Volunteers
- 24 people
- Sponsor
- British Columbia Cancer Agency
Orbital Lymphoma
Radiotherapy 12Gy in 6 Fractions For Orbital Lymphoma
Current standard RT doses (24-25Gy) provide excellent disease control for patients with indolent B-cell orbital lymphoma, but can cause significant late toxicities.
- Trial name
- NCT07210749
- Testing
- External Beam Radiation Therapy
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- British Columbia Cancer Agency
Neuroendocrine Tumors, NET, Pheochromocytoma/Paraganglioma
A Comparison of [68Ga]DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine Malignancies
Neuroendocrine tumours (NETs) are generally slow growing, but some can be aggressive and resistant to treatment. Compared to healthy cells, the surface of these tumor cells has a greater number of molecules called somatostatin…
- Conditions
- Neuroendocrine Tumors, NET, Pheochromocytoma/Paraganglioma, SSTR-expressing Tumors, Medullary Thyroid Carcinoma
- Trial name
- NET-COMPARE (NCT07621146)
- Testing
- 68Ga-DOTATATE PET/CT, 18F-AmBF3-TATE PET/CT
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- British Columbia Cancer Agency
Prostate Neoplasm
Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)
Men with castrate resistant prostate cancer who are switched from a luteinizing hormone-releasing hormone (LHRH) antagonists from a LHRH agonist will experience a fall in prostate-specific antigen (PSA).
- Trial name
- NCT01630967
- Testing
- Degarelix
- Where
- Canada
- Sponsor
- British Columbia Cancer Agency
Diffuse Large B-cell Lymphoma, Multiple Myeloma
Preliminary Assessment of [18F]BL40 in PET/CT Scans
CXCR4 is type of receptor that has been detected in more than twenty different subtypes of cancers. Most of these cancers are associated with negative symptoms that worsen over time resulting in great disability and poor…
- Conditions
- Diffuse Large B-cell Lymphoma, Multiple Myeloma, Mantle Cell Lymphoma, Marginal Zone Lymphoma
- Trial name
- NCT06224309
- Testing
- 18F-BL40 PET/CT, 18F-FDG PET/CT, Routine Blood Draw - Phase 1 only
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- British Columbia Cancer Agency
Metastatic Tumors
Stereotactic Ablative Body Radiotherapy (SABR) for Oligometastases
This is a study measuring toxicity while making observations about the survival benefits of treating participants with oligometastatic disease using stereotactic ablative radiotherapy (SABR).
- Trial name
- NCT02933242
- Testing
- Stereotactic Ablative Body Radiotherapy
- Where
- Canada
- Volunteers
- 399 people
- Sponsor
- British Columbia Cancer Agency
Multiple Cancers, Multiple Indications Cancer
HELP Study - Towards High Throughput and Efficient Long-axial PET With Oral [18F]FDG
Typically, PET scans involve an IV injection of 18F-FDG that helps identify cancer. Patients are scanned 60 minutes after injecting 18F-FDG.
- Conditions
- Multiple Cancers, Multiple Indications Cancer, Feasibility Studies
- Trial name
- HELP (NCT07295171)
- Testing
- Oral FDG scan
- Where
- Canada
- Volunteers
- 27 people
- Sponsor
- British Columbia Cancer Agency
Brain Metastases, Adult
RAPid SimPLE Targeted Radiation Treatment for Brain Metastases
The aim of the study is to show that rapid, simple targeted radiotherapy to brain metastases with 8 Gy / 1 is non-inferior to 20 Gy / 5 in terms of overall survival for patients with poor prognosis.
- Trial name
- RAPPLE (NCT05050929)
- Testing
- Targeting All Brain Metastases
- Where
- 6 sites in Canada
- Volunteers
- 100 people
- Sponsor
- British Columbia Cancer Agency
Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment
The goal of this study is to learn if the genetic information and proteins from tumours can help treat pancreatic ductal adenocarcinoma (PDAC).
- Conditions
- Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma
- Trial name
- ACCELERATE (NCT06574620)
- Testing
- Genetic testing, Optional biopsy, Tissue collection
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- British Columbia Cancer Agency
Breast Cancer, Lung Cancer
Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity
This study will investigate the effects of atezolizumab on select cancer types in people whose analysis of tumour DNA and RNA indicates they may be sensitive to atezolizumab.
- Conditions
- Breast Cancer, Lung Cancer, Gastrointestinal Cancer, Genitourinary Cancer
- Trial name
- CAPTIV-8 (NCT04273061)
- Testing
- Atezolizumab
- Where
- 2 sites in Canada
- Volunteers
- 50 people
- Sponsor
- British Columbia Cancer Agency
Pancreatic Ductal Adenocarcinoma (PDAC), Hand Grip Strength
Using Strength Tests to Better Understand How Pancreatic Cancer Affects Muscle Mass and Quality of Life
The goal of this clinical trial is to measure hand grip strength in adults with pancreatic ductal adenocarcinoma (PDAC). The main questions it aims to answer are: Is it feasible to measure hand grip strength as part of a clinic…
- Trial name
- PanFit (NCT07255001)
- Testing
- Hand grip strength assessments using a dynamometer
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- British Columbia Cancer Agency
Cancer, Pancreatic Cancer
Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis
Researchers are looking for better ways of understanding and treating pancreatic cancer. The purpose of this study is to see how useful it is to look for changes and characteristics in your genes (molecules that contain…
- Trial name
- PanGen (NCT02869802)
- Testing
- Tumour Biopsy, Serial Collection of Plasma and Serum Samples
- Where
- 4 sites in Canada
- Volunteers
- 190 people
- Sponsor
- British Columbia Cancer Agency
Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma
Monitoring and Managing Glucose Levels in People With Pancreatic Cancer
This study will investigate the prevalence of hyperglycemia (high blood sugar) in approximately 50 participants with pancreatic cancer.
- Conditions
- Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Hyperglycemia
- Trial name
- PEGASUS (NCT05132244)
- Testing
- Glucose Measurements via Blood Draw
- Where
- 2 sites in Canada
- Volunteers
- 50 people
- Sponsor
- British Columbia Cancer Agency
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Single vs Hypofractionated Irradiation For Timely Access to Partial Breast Radiotherapy
Partial Breast Irradiation (PBI) is a targeted radiation approach commonly administered post-lumpectomy, specifically targeting the tumour bed.
- Trial name
- NCT06885671
- Testing
- Multiple Fraction PBI, Single Fraction PBI
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- British Columbia Cancer Agency
Metastases, Palliative Radiotherapy
High Dose Radiotherapy for Palliation (Hi-D)
Palliative radiation is effective for controlling or preventing symptoms such as pain, bleeding, dyspnea, and cord compression. Recently, studies have shown that additional dose escalation may result in superior local control.
- Trial name
- NCT07291895
- Testing
- Palliative Radiotherapy
- Where
- Canada
- Volunteers
- 21 people
- Sponsor
- British Columbia Cancer Agency